Kevin Kalinsky, MD, MS, on Implications of the Phase 3 RxPONDER Trial in Breast Cancer

Article

The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.

A study presented at the 2020 San Antonio Breast Cancer Symposium found that menopausal status may determine clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine; director of the Glenn Family Breast Center and director of breast medical oncology at Winship Cancer Institute of Emory University, spoke to CancerNetwork about the trial results and their implications.

Transcription:

So, I think that this study is practice changing. And I think that for the postmenopausal group, when you look at two-thirds of the population, when you look at those curves, they fully overlap. There was a hazard ratio of 0.97 and those curves look exactly the same. And there was no benefit even when we did a forest plot of any subgroups and postmenopausal women who are benefiting from chemo. So, for the postmenopausal group, you know, that spares thousands of women, the cost and the toxicity, and all the other issues that can be associated with getting chemotherapy.

Now in the premenopausal group, there was a statistically significant improvement within invasive disease-free survival and also a 1.3% absolute improvement in survival in the group that were randomized to chemotherapy. So you know, that has huge implications for when we sit down with our patients, and we explain to them, “Well, listen, these are the benefits and these are the risks.” This study helps inform those discussions.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content